However, only the methylation of septin-9 (SEPT9) was translated into clinical application for screening colon cancer approved by the FDA in 2016, with variable values of sensitivity (58–95.6%) and specificity (69–97.1%) [7]. Here, SEPTIN9 is linked to malignant colon neoplasm.